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Abstract
Introduction Transforming growth factor-β (TGF-β) is a potent
suppressor of mammary epithelial cell (MEC) proliferation and is
thus an inhibitor of mammary tumor formation. Malignant MECs
typically evolve resistance to TGF-β-mediated growth arrest,
enhancing their proliferation, invasion, and metastasis when
stimulated by TGF-β. Recent findings suggest that therapeutics
designed to antagonize TGF-β signaling may alleviate breast
cancer progression, thereby improving the prognosis and
treatment of breast cancer patients. We identified the cysteine
protease inhibitor cystatin C (CystC) as a novel TGF-β type II
receptor antagonist that inhibits TGF-β binding and signaling in
normal and cancer cells. We hypothesized that the oncogenic
activities of TGF-β, particularly its stimulation of mammary
epithelial–mesenchymal transition (EMT), can be prevented by
CystC.
Method Retroviral infection was used to constitutively express
CystC or a CystC mutant impaired in its ability to inhibit
cathepsin protease activity (namely ∆14CystC) in murine
NMuMG MECs and in normal rat kidney (NRK) fibroblasts. The
effect of recombinant CystC administration or CystC expression
on TGF-β stimulation of NMuMG cell EMT in vitro was
determined with immunofluorescence to monitor
rearrangements of actin cytoskeletal architecture and E-
cadherin expression. Soft-agar growth assays were performed
to determine the effectiveness of CystC in preventing TGF-β
stimulation of morphological transformation and anchorage-
independent growth in NRK fibroblasts. Matrigel invasion
assays were performed to determine the ability of CystC to
inhibit NMuMG and NRK motility stimulated by TGF-β.
Results CystC and ∆14CystC both inhibited NMuMG cell EMT
and invasion stimulated by TGF-β by preventing actin
cytoskeletal rearrangements and E-cadherin downregulation.
Moreover, both CystC molecules completely antagonized TGF-
β-mediated morphological transformation and anchorage-
independent growth of NRK cells, and inhibited their invasion
through synthetic basement membranes. Both CystC and
∆14CystC also inhibited TGF-β signaling in two tumorigenic
human breast cancer cell lines.
Conclusion Our findings show that TGF-β stimulation of
initiating metastatic events, including decreased cell
polarization, reduced cell–cell contact, and elevated cell
invasion and migration, are prevented by CystC treatment. Our
findings also suggest that the future development of CystC or its
peptide mimetics hold the potential to improve the therapeutic
response of human breast cancers regulated by TGF-β.
Introduction
Oncogenic epithelial–mesenchymal transitions (EMTs) com-
prise a complex array of gene expression and repression that
elicits tumor metastasis in localized carcinomas [1,2]. The
acquisition of metastatic phenotypes by dedifferentiated
tumors is the most lethal facet of cancer and is the leading
cause of cancer-related death [3,4]. Transforming growth fac-
tor-β (TGF-β) is a powerful tumor suppressor that normally
represses these processes by prohibiting epithelial cell prolif-
eration, and by creating a cell microenvironment that inhibits
epithelial cell motility, invasion, and metastasis [5,6]. Carcino-
genesis often subverts the tumor-suppressing function of
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TGF-β, thereby endowing TGF-β with oncogenic activities that
promote the growth and spread of developing tumors, includ-
ing the initiation and stabilization of tumor EMT [1,2,5-7]. The
duality of TGF-β in both suppressing and promoting cancer
development was observed originally with transgenic TGF-β1
expression in mouse keratinocytes, which initially suppressed
benign skin tumor formation before promoting malignant con-
version and spindle cell carcinoma generation [8]. More
recently, TGF-β signaling was shown to inhibit the tumori-
genicity of normal, premalignant, and malignant breast epithe-
lial cells, while stimulating that of highly invasive and
metastatic breast cancer cells [9]. Fundamental gaps exist in
our knowledge of how malignant cells overcome the cytostatic
actions of TGF-β and of how TGF-β stimulates the progres-
sion of developing tumors. Indeed, these knowledge gaps
have prevented science and medicine from developing treat-
ments effective in antagonizing TGF-β oncogenicity in pro-
gressing cancers, particularly those of the breast.
The ability of TGF-β to induce cancer growth and metastasis
suggests that developing therapeutics to antagonize and/or
circumvent TGF-β signaling may prove effective in treating
metastatic malignancies, perhaps by preventing the stimula-
tion of EMT by TGF-β. Cystatin C (CystC) is a small, ubiqui-
tously expressed cysteine protease inhibitor found in nearly all
bodily fluids [10,11]. By inactivating cathepsin protease activ-
ities, CystC reduces bone resorption, neutrophil chemotaxis,
and tissue inflammation, and also inhibits cancer cell invasion
[10]. We showed recently that CystC not only inhibits cathep-
sin-mediated invasion but also antagonizes TGF-β signaling in
normal and cancer cells by interacting physically with the TGF-
β type II receptor (TβR-II), thereby preventing TGF-β binding
[12]. Thus, CystC is a novel TβR-II antagonist that may prove
useful in blocking the oncogenic activities of TGF-β, particu-
larly its ability to stimulate EMT. In the present study we tested
this hypothesis by measuring the ability of CystC to antagonize
the oncogenic activities of TGF-β in two established in vitro
models of cancer progression: first, EMT of normal murine
NMuMG mammary epithelial cells (MECs), and second, mor-
phological transformation and anchorage-independent growth
of normal rat kidney (NRK) fibroblasts. We show that CystC
significantly decreased TGF-β stimulation of EMT and mor-
phological transformation in mammary epithelial cells and kid-
ney fibroblasts, respectively. We show further that CystC
significantly antagonized TGF-β signaling in two tumorigenic
human breast cancer cell lines. Thus, by antagonizing TGF-β
signaling and preventing its stimulation of EMT, CystC may
represent a novel TGF-β chemopreventive agent effective in
neutralizing the tumor-promoting activities of TGF-β and its
stimulation of tumor metastasis.
Materials and methods
Recombinant CystC expression and purification
The synthesis of bacterial expression vectors encoding human
CystC or ∆14CystC fused to the carboxy terminus of glutath-
ione S-transferase (GST), and their purification from trans-
formed Escherichia coli, were described previously [12].
Retroviral CystC expression
The creation of bicistronic retroviral vectors (namely pMSCV-
IRES–GFP, where GFP stands for green fluorescent protein)
encoding human CystC or ∆14CystC was described previ-
ously [12]. Mouse NMuMG, rat NRK kidney fibroblasts, and
human MDA-MB-231 and MCF10A-CA1a breast cancer cells
were infected overnight with control (pMSCV-IRES–GFP),
CystC, or ∆14CystC retroviral supernatants produced by
EcoPac2 retroviral packaging cells (Clontech) as described
[12]. Cells expressing GFP were isolated and collected 48
hours later on a MoFlo cell sorter (Cytomation), and were sub-
sequently expanded to yield stable polyclonal populations of
control, CystC-expressing, or ∆14CystC-expressing cells. The
expression and secretion of recombinant CystC proteins by
individual infected cell lines were monitored by immunoblot-
ting conditioned medium with anti-CystC antibodies as
described [12].
Immunofluorescence studies
The ability of TGF-β to alter actin cytoskeletal architecture and
E-cadherin expression was monitored essentially as described
[13]. In brief, control, CystC-expressing, or ∆14CystC-
expressing NMuMG cells were allowed to adhere overnight to
glass coverslips in 24-well plates (50,000 cells per well). The
cells were stimulated the following day with TGF-β1 (5 ng/ml)
for 0 to 36 hours at 37°C. In some experiments, control
NMuMG cells were stimulated with TGF-β1 in the absence or
presence of 10 µg/ml recombinant GST, GST–CystC, or
GST–∆14CystC. On completion of agonist stimulation, the
cells were washed in ice-cold PBS and immediately fixed in
3.7% formaldehyde. After extensive washing in PBS, the cells
were blocked in PBS supplemented with 1.5% FBS, followed
by incubation with rhodamine–phalloidin (0.25 µM). Alterna-
tively, the cells were blocked in goat γ-globulin (200 µg/ml;
Jackson Immunoresearch) before the detection of E-cadherin
by sequential incubations with monoclonal anti-E-cadherin
(1:50 dilution; BD Bioscience), followed by biotinylated goat
anti-mouse antibody (5 µg/ml; Jackson Immunoresearch), and
finally by Alexa-streptavidin (1.2 µg/ml; Molecular Probes).
Images were captured on a Nikon Diaphot microscope.
The ability of TGF-β to alter E-cadherin expression was also
monitored by immunoprecipitating E-cadherin from buffer H/
Triton (1.5 mM EGTA, 50 mM β-glycerophosphate, 1 mM DTT,
0.2 mM Na3VO4, 1 mM benzamidine, 10 µg/ml Leupeptin, 10
µg/ml aprotinin, and 1% Triton X-100; pH 7.3) [14]. NMuMG
whole cell extracts (250 µg per tube), followed by immunob-
lotting with anti-E-cadherin antibodies (1:1000 dilution). In
other experiments, an aliquot of NMuMG whole cell extract
was removed before immunoprecipitation of E-cadherin and
used to control for differences in protein loading byAvailable online http://breast-cancer-research.com/content/7/5/R844
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immunoblotting for extracellular signal-related kinase 1/2.
Both assay protocols yielded similar results.
Cell biological assays
The effect CystC or ∆14CystC on various MECs (such as
NMuMG, MCF10A-CA1a, or MDA-MB-231) or NRK cell activ-
ities was determined as follows: first, cell proliferation with a
[3H]thymidine incorporation assay as described [14,15]; sec-
ond, cell invasion with a modified Boyden-chamber assay and
Matrigel matrices as described [12,15]; and third, gene
expression with pSBE-luciferase and p3TP-luciferase reporter
gene assays as described [12,14].
In addition, the effect of recombinant GST, CystC, or
∆14CystC on Smad2 phosphorylation stimulated by TGF-β
was determined by allowing MDA-MB-231 cells (100,000
cells per well) to adhere overnight to 24-well plates. The fol-
lowing morning, the cells were washed twice in ice-cold PBS
Figure 1
CystC and ∆14CystC inhibit actin cytoskeletal rearrangements stimulated by TGF-β in NMuMG cells CystC and ∆14CystC inhibit actin cytoskeletal rearrangements stimulated by TGF-β in NMuMG cells. (a) NMuMG cells were infected with ecotropic 
retrovirus encoding either green fluorescent protein (GFP; control), CystC, or ∆14CystC, and subsequently were isolated by fluorescence-activated 
cell sorting for GFP expression to yield stable polyclonal populations of control, CystC-expressing, and ∆14CystC-expressing cells as indicated 
(upper panel). The expression and secretion of recombinant CystC proteins by infected NMuMG cells were monitored by immunoblotting condi-
tioned medium with anti-CystC antibodies (lower panel). (b) Control, CystC-expressing, and ∆14CystC-expressing NMuMG cells were incubated in 
the absence or presence of transforming growth factor-β1 (TGF-β1; 5 ng/ml) for 8 hours, whereupon alterations in actin cytoskeletal architecture 
were revealed by direct rhodamine–phalloidin immunofluorescence. Shown are representative images from a single experiment that was repeated 
twice with identical results. (c) NMuMG cells were stimulated with TGF-β1 (5 ng/ml) for 0 to 24 hours in the presence of either glutathione S-trans-
ferase (GST), GST–CystC, or GST–∆14CystC (each at 10 µg/ml) as indicated. Afterward, altered actin cytoskeletal architecture was revealed by 
direct rhodamine–phalloidin immunofluorescence. Shown are representative images from a single experiment that was repeated once with identical 
results.Breast Cancer Research    Vol 7 No 5    Sokol et al.
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and incubated in serum-free medium supplemented with 25
µg/ml recombinant GST, CystC, or ∆14CystC for 2 hours at
37°C. Afterward, the cells were stimulated with TGF-β1 (1 ng/
ml) for 30 min at 37°C, and subsequently were subjected to
phospho-Smad2 immunoblot analyses as described [14].
Soft agar assay
The growth of NRK cells in soft agar was performed as
described [16]. In brief, duplicate cultures of control, CystC-
expressing, or ∆14CystC-expressing NRK cells (10,000 cells
per plate) were grown in 0.3% agar on a cushion of 0.6% agar
in 35 mm plates. NRK cell growth in the absence or presence
of 5 ng/ml TGF-β1 was allowed to proceed for 7 days, where-
upon the number of colonies formed was quantified under a
light microscope.
Results
CystC prevents TGF-β stimulation of EMT in NMuMG 
cells
The importance of EMT in promoting cancer progression and
tumor metastasis is becoming increasingly apparent [1,2].
Although the formation and growth of early-stage tumors is
normally suppressed by TGF-β, cancer progression typically
enables TGF-β to stimulate the growth and metastasis of late-
stage tumors, in part through its induction of EMT [2]. We
recently identified the cysteine protease inhibitor CystC as a
novel TβR-II antagonist [12]. Indeed, the physical association
of CystC with TβR-II not only prevented TGF-β binding and,
consequently, TGF-β signaling in normal and cancer cells, but
it also inhibited their invasion through synthetic basement
membranes [12]. Collectively, these findings led us to propose
CystC as a novel chemopreventive agent capable of antago-
nizing the tumor-promoting activities of TGF-β in late-stage
tumors, particularly the ability of TGF-β to induce EMT.
To test this hypothesis, we first overexpressed in NMuMG
cells (Fig. 1a) either CystC or a CystC mutant impaired in its
ability to inhibit cathepsin protease activity (namely ∆14CystC
[12]) to determine whether they could antagonize TGF-β stim-
ulation of EMT. As described previously [12], ∆14CystC pro-
tein migrates more slowly in SDS-PAGE than its wild-type
counterpart, because of additional amino-terminal amino acids
appended to ∆14CystC during the shuttling of its cDNA
through the pSecTag vector. Unlike HT1080 and 3T3-L1
cells, the expression of ∆14CystC in NMuMG cells results in
the production of two distinct ∆14CystC molecules (Fig. 1a).
Although they are currently unknown, we suspect that the two
recombinant  ∆14CystC species observed in transduced
NMuMG cells most probably result from differences in glyco-
sylation [17,18]. Nonetheless, these stable populations of
NMuMG cells were used to examine the effects of CystC or
∆14CystC on NMuMG cell EMT.
In contrast to the situation in developing tissues, inappropriate
induction of EMT by TGF-β in adult tissues enhances tumori-
Figure 2
CystC and ∆14CystC antagonize E-cadherin downregulation stimu- lated by TGF-β in NMuMG cells CystC and ∆14CystC antagonize E-cadherin downregulation stimu-
lated by TGF-β in NMuMG cells. (a) Control, CystC-expressing, and 
∆14CystC-expressing NMuMG cells were incubated in the absence or 
presence of transforming growth factor-β1 (TGF-β1; 5 ng/ml) for 36 
hours, whereupon alterations in E-cadherin expression was monitored 
by immunoprecipitation and subsequent immunoblotting with anti-E-
cadherin antibodies. The representative immunoblot depicts the down-
regulation of E-cadherin expression induced by TGF-β in NMuMG cells. 
The lower panel shows the alterations in E-cadherin expression (means 
± SEM) induced by TGF-β relative to their untreated counterparts 
observed in three independent experiments. TGF-β significantly down-
regulated E-cadherin expression in NMuMG cells (*P < 0.05; Student's 
t-test). (b) NMuMG cells were stimulated with TGF-β1 (5 ng/ml) for 36 
hours in the presence of glutathione S-transferase (GST) fusion pro-
teins (10 µg/ml) as indicated. E-cadherin expression was monitored by 
indirect immunofluorescence with anti-E-cadherin antibodies. Shown 
are representative images from a single experiment that was repeated 
once with identical results.Available online http://breast-cancer-research.com/content/7/5/R844
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genesis [2,19]. TGF-β stimulation of EMT is studied routinely
in murine NMuMG MECs, which readily undergo EMT when
treated with TGF-β [13,20,21]. Unstimulated NMuMG cells
exhibited typical epithelial cuboidal morphology characterized
by strong cortical and diffuse cytoplasmic actin staining (Fig.
1b). In response to TGF-β, NMuMG cells undergo transition
into fibroblasts and exhibit distinct actin stress fibers emanat-
ing from focal adhesions (Fig. 1b). This NMuMG cell response
to TGF-β was prevented by the overexpression of either CystC
or ∆14CystC (Fig. 1b). Similarly, treatment of NMuMG cells
with recombinant CystC or ∆14CystC prevented TGF-β stim-
ulation of actin cytoskeletal reorganization at 8 hours, and sig-
nificantly reduced this response at 24 hours (Fig. 1c).
TGF-β stimulation downregulates E-cadherin expression in
MECs undergoing EMT [13]. We, too, find that TGF-β stimu-
lation reduced NMuMG cell expression of E-cadherin and,
more importantly, that CystC or ∆14CystC overexpression in
or recombinant CystC or ∆14CystC treatment of NMuMG
cells significantly attenuated the ability of TGF-β to downregu-
late E-cadherin expression (Fig. 2a, b). Figure 3a shows that
TGF-β potently inhibited DNA synthesis in NMuMG cells.
Quite surprisingly, CystC or ∆14CystC expression had little
effect on the sensitivity of NMuMG cells to TGF-β-mediated
growth arrest, despite the fact that both CystC molecules sig-
nificantly inhibited tonic NMuMG cell proliferation (Fig. 3a). In
addition, NMuMG cells undergoing EMT exhibit elevated inva-
sion through synthetic basement membranes (Fig. 3b). We
showed previously that, first, the invasion of 3T3-L1 cells
through Matrigel matrices proceeds through pathways
dependent on cathepsin and on TGF-β, and second, CystC
abrogates both pathways, whereas ∆14CystC selectively
blocks the TGF-β-dependent pathway [12]. Similarly to their
actions on 3T3-L1 cells, the expression of CystC and
∆14CystC also inhibited and delineated cathepsin-dependent
and TGF-β-dependent invasion in NMuMG cells (Fig. 3b). Col-
lectively, these findings show that CystC and ∆14CystC do
indeed effectively inhibit mammary cell EMT and invasion stim-
ulated by TGF-β. Moreover, these findings suggest that when
interacting with TβR-II, CystC alters the TGF-β receptor sign-
aling complex in a manner that selectively inhibits some TGF-
β functions (such as EMT) while leaving others (such as
growth arrest) intact.
CystC inhibits TGF-β signaling in human breast cancer 
cells
Because NMuMG cells are non-tumorigenic and an incom-
plete model of breast cancer progression, we also determined
whether CystC antagonizes TGF-β signaling in human breast
cancer cells. To do so, we first stably expressed CystC in
human MCF10A-CA1a breast cancer cells, whose metastatic
activity is enhanced by TGF-β [9]. Given this fact, we hypoth-
esized that TGF-β would stimulate the growth of MCF10A-
CA1a cells in soft agar. In stark contrast, we found TGF-β stim-
ulation to suppress the growth of MCF10A-CA1a cells in soft
Figure 3
CystC and ∆14CystC inhibit NMuMG cell proliferation and invasion CystC and ∆14CystC inhibit NMuMG cell proliferation and invasion. (a) 
Control, CystC-expressing, or ∆14CystC-expressing NMuMG cells 
were incubated with increasing concentrations of transforming growth 
factor-β1 (TGF-β1; from 0 to 5 ng/ml) for 48 hours. Cellular DNA was 
radiolabeled with [3H]thymidine and quantified by scintillation counting. 
Data are means ± SEM for two independent experiments presented as 
the percentage [3H]thymidine incorporation normalized to untreated 
control cells. CystC and ∆14CystC both significantly decreased DNA 
synthesis in resting NMuMG cells (*P < 0.05; Student's t-test). (b) 
Control, CystC-expressing, and ∆14CystC-expressing NMuMG cells 
were allowed to invade through Matrigel matrices in the absence or 
presence of TGF-β1 (5 ng/ml) for 48 hours. Values are means ± SEM 
for three independent experiments presented as the percentage inva-
sion relative to GFP-expressing NMuMG cells. TGF-β1 significantly 
enhanced NMuMG cell invasion (*P < 0.05; Student's t-test), a 
response that was inhibited significantly by CystC and ∆14CystC 
expression (#P < 0.05; Student's t-test). CystC expression also signifi-
cantly inhibited tonic NMuMG cell invasion (*P < 0.05; Student's t-
test).Breast Cancer Research    Vol 7 No 5    Sokol et al.
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agar, a response that was unaffected by CystC expression
(data not shown). However, CystC expression did significantly
inhibit the anchorage-independent growth of MCF10A-CA1a
cells (Fig. 4a), as well as significantly antagonized reporter
gene expression stimulated by TGF-β (Fig. 4b).
We also investigated whether the inhibitory effects of CystC
on TGF-β signaling were unique to MCF10A-CA1a cells or
were instead a more generalized inhibitory mechanism of TGF-
β signaling in human breast cancers. As shown in Fig. 5a, over-
expression of CystC or ∆14CystC in human MDA-MB-231
breast cancer cells significantly reduced reporter gene
expression stimulated by moderate TGF-β concentrations
(such as 0.5 ng/ml), an effect that was overcome by
stimulation with supraphysiological TGF-β concentrations
(such as 5 ng/ml). Accordingly, treatment of MDA-MB-231
cells with recombinant CystC or ∆14CystC significantly
antagonized reporter gene expression induced by TGF-β (Fig.
5b) and inhibited its ability to stimulate Smad2 phosphoryla-
tion (Fig. 5c). Taken together, these findings establish CystC
and its derivative ∆14CystC as novel TGF-β antagonists in
human breast cancer cells.
CystC prevents stimulation of morphological 
transformation in NRK cells by TGF-β
The loss of cell polarity and the ability of cancer cells to grow
autonomously in an anchorage-independent manner are a hall-
mark of cancer [1,2]. TGF-β was originally described as a
secreted factor that stimulates morphological transformation
in rat NRK-49 kidney cells, leading to their acquisition of
anchorage-independent growth in soft agar [22,23]. Thus, in
addition to promoting EMT, TGF-β also enhances cancer pro-
gression by stimulating morphological transformation and
anchorage-independent cell growth. Because CystC and
∆14CystC both eliminated EMT stimulated by TGF-β, we
hypothesized that these TβR-II antagonists [12] would simi-
larly inhibit NRK cell morphological transformation stimulated
by TGF-β. We tested this hypothesis by infecting NRK cells
with bicistronic retrovirus encoding either CystC or ∆14CystC
(Fig. 6a) to determine their effects on NRK anchorage-inde-
pendent growth stimulated by TGF-β. As expected, treatment
with TGF-β enabled NRK cells to grow in an anchorage-inde-
pendent manner when cultured in soft agar (Fig. 6b). Similar to
their inhibitory activities in NMuMG and breast cancer cells,
retroviral-mediated expression of CystC or ∆14CystC in NRK
cells prevented their morphological transformation stimulated
by TGF-β (Fig. 6b), as well as inhibiting Smad2/3-mediated
reporter gene expression (Fig. 6c) and cell invasion induced
by TGF-β (Fig. 6d). Thus, in addition to preventing TGF-β stim-
ulation of EMT and inhibiting TGF-β signaling in breast cancer
cells, CystC and ∆14CystC also antagonize morphological
transformation and anchorage-independent growth stimulated
by TGF-β.
Figure 4
CystC antagonizes TGF-β signaling in human MCF10A-CA1a breast  cancer cells CystC antagonizes TGF-β signaling in human MCF10A-CA1a breast 
cancer cells. (a) Control and CystC-expressing MCF10A-CA1a cells 
were cultured in soft agar for 14 days, whereupon MCF10A-CA1a col-
ony formation was quantified by light microscopy. Values are colony for-
mation per microscope field (means ± SEM) observed in two 
independent experiments. CystC expression significantly reduced 
anchorage-independent growth of MCF10A-CA1a cells (*P < 0.05; 
Student's t-test). (b) Control and CystC-expressing MCF10A-CA1a 
cells were transiently transfected with p3TP-luciferase and pCMV-β-
Gal cDNAs, and were subsequently stimulated with transforming 
growth factor-β1 (TGF-β1; 0.5 ng/ml) for 24 hours. Afterward, luci-
ferase and β-Gal activities contained in detergent-solubilized cell 
extracts were measured. Values are luciferase activities (means ± SEM) 
observed in two independent experiments normalized to the maximal 
reporter gene expression stimulated by TGF-β in cells expressing green 
fluorescent protein. CystC expression significantly inhibited luciferase 
expression induced by TGF-β (*P < 0.05; Student's t-test).Available online http://breast-cancer-research.com/content/7/5/R844
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Discussion
TGF-β is widely expressed during development to regulate the
interactions between epithelial and mesenchymal cells, partic-
ularly those in the lung, kidney, and mammary gland. Inappro-
priate reactivation of EMT during tumorigenesis is now
recognized as an important process necessary for the acquisi-
tion of invasive and metastatic phenotypes by tumors [1,2]. By
cooperating with oncogenes and growth factors, TGF-β
potently induces EMT and serves to stabilize this transition by
means of autocrine signaling. Moreover, these events seem to
underlie the oncogenic activities of TGF-β and its ability to pro-
mote cancer progression [20,24-26]. A comprehensive under-
standing of how TGF-β both suppresses and promotes
tumorigenesis remains an unknown and fundamental question
that directly affects our ability to effectively target the TGF-β
signaling system during the treatment of human malignancies,
particularly those of the breast. Indeed, solving this paradox
remains the most important aspect of the biological and path-
ological actions of this multifunctional cytokine.
Despite recent advances in understanding the molecular
mechanisms underlying EMT, the question of how to prevent
this process effectively in response to TGF-β remains unan-
swered. We recently discovered that CystC antagonizes TGF-
β signaling in normal and cancer cells by interacting physically
with TβR-II, thereby preventing TGF-β binding [12]. Impor-
tantly, we demonstrated the effectiveness of CystC in inhibit-
ing the invasion of cancer cells and the TGF-β-stimulated
invasion of fibroblasts [12]. Because EMT is necessary for the
acquisition of invasive and metastatic phenotypes by cancer
cells, and because CystC inhibited TGF-β-stimulated invasion,
we proposed CystC as a potential antagonist of EMT stimu-
lated by TGF-β.
Accordingly, in this study we show that CystC and ∆14CystC
both prevent EMT and its associated increase in MEC motility
(Figs 1, 2, 3), as well as antagonizing TGF-β signaling in
human breast cancer cells (Figs 4 and 5). We further show for
the first time that these CystC molecules inhibit TGF-β signal-
ing in NRK fibroblasts, thus preventing their morphological
transformation and invasion through synthetic basement mem-
branes (Fig. 6). Although our understanding of CystC function
in regulating TGF-β signaling is in its infancy, our findings sug-
gest that this protease inhibitor might provide an innovative
model for the development of novel TβR-II antagonists
designed to combat the stimulation of tumor progression and
EMT by TGF-β. We further propose that the chemopreventive
effectiveness of CystC will be potentiated by its inhibition of
cathepsin B-mediated invasion and metastasis [27-30] and its
inhibition of the cathepsin B-mediated activation of latent TGF-
β [31-33], which co-localizes with cathepsin B to the invading
face of malignant tumors [34-37]. Moreover, CystC-mediated
cathepsin B inactivation will reduce the activity of the uroki-
nase plasminogen system, which enhances tumor cell extra-
cellular matrix degradation, as well as growth factor and latent
Figure 5
CystC and ∆14CystC inhibit TGF-β signaling in human MDA-MB-231  breast cancer cells CystC and ∆14CystC inhibit TGF-β signaling in human MDA-MB-231 
breast cancer cells. (a) Control, CystC-expressing, or ∆14CystC-
expressing MDA-MB-231 cells were transiently transfected with p3TP-
luciferase and pCMV-β-Gal cDNAs, and were subsequently stimulated 
with increasing concentrations of transforming growth factor-β1 (TGF-
β1; from 0 to 5 ng/ml) for 24 hours. Afterward, luciferase and β-Gal 
activities contained in detergent-solubilized cell extracts were meas-
ured. Values are luciferase activities (means ± SEM) observed in two 
independent experiments normalized to maximal reporter gene expres-
sion in TGF-β-stimulated cells expressing green fluorescent protein. 
CystC and ∆14CystC both significantly inhibit reporter gene expres-
sion stimulated by TGF-β (*P < 0.05; Student's t-test). (b) MDA-MB-
231 cells were transiently transfected with p3TP-luciferase and pCMV-
β-Gal cDNAs. Afterward, the transfectants were treated with 25 µg/ml 
recombinant glutathione S-transferase (GST; G), CystC (C), or 
∆14CystC (D) and immediately stimulated with TGF-β1 (1 ng/ml) for 
24 hours before determination of the luciferase and β-Gal activities 
contained in detergent-solubilized cell extracts. Values are luciferase 
activities (means ± SEM) observed in four independent experiments 
normalized to maximal reporter gene expression stimulated by TGF-β in 
GST-treated cells. (c) MDA-MB-231 cells were treated with 25 µg/ml 
recombinant GST (G), CystC (C), or ∆14CystC (D) for 2 hours before 
their stimulation with TGF-β (1 ng/ml) for 30 min. Afterward, the activa-
tion status of Smad2 was determined by immunoblot analysis with 
phospho-specific Smad2 antibodies. Differences in protein loading 
were monitored by reprobing stripped membranes with antibodies 
against extracellular signal-related kinase 1. Data are from a representa-
tive experiment that was repeated once with similar results.Breast Cancer Research    Vol 7 No 5    Sokol et al.
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Figure 6
CystC and ∆14CystC inhibit NRK cell morphological transformation and anchorage-independent growth stimulated by TGF-β CystC and ∆14CystC inhibit NRK cell morphological transformation and anchorage-independent growth stimulated by TGF-β. (a) Normal rat kidney 
(NRK) fibroblasts were infected with control (namely pMSCV-IRES–GFP, where GFP stands for green fluorescent protein), CystC, or ∆14CystC 
retroviral supernatants as in Fig. 1a, and the resulting infected cells were isolated by GFP fluorescence on a MoFlo cell sorter 48 hours later. Shown 
in the upper panel are the GFP expression profiles of the resulting polyclonal populations. Also shown, in the lower panel, are recombinant CystC 
(CC) and ∆14CystC (∆14) proteins present in conditioned medium of individual NRK populations and revealed by anti-CystC immunoblotting. (b) 
Control, CystC-expressing, and ∆14CystC-expressing NRK cells were cultured in soft agar in the absence or presence of transforming growth fac-
tor-β1 (TGF-β1; 5 ng/ml) for 7 days, whereupon NRK colony formation was quantified by light microscopy (upper panel). Middle panel, magnification 
of boxed regions. Lower panel, colony formation per microscope field (means ± SEM) observed in five independent experiments. (c) Control, CystC-
expressing, or ∆14CystC-expressing NRK cells were transiently transfected with pSBE-luciferase and pCMV-β-Gal cDNAs, and were subsequently 
stimulated with TGF-β1 (5 ng/ml) for 24 hours. Afterward, luciferase and β-Gal activities contained in detergent-solubilized cell extracts were meas-
ured. Values are luciferase activities (means ± SEM) observed in three independent experiments normalized to maximal reporter gene expression 
induced by TGF-β in GFP-expressing cells. CystC expression significantly inhibited luciferase expression induced by TGF-β (*P < 0.05; Student's t-
test). (d) Control, CystC-expressing, and ∆14CystC-expressing NRK cells were allowed to invade through Matrigel matrices in the absence or pres-
ence of TGF-β1 (5 ng/ml) for 48 hours. Values are means ± SEM for three independent experiments presented as the percentage invasion relative 
to GFP-expressing NRK cells. TGF-β1 significantly enhanced NRK cell invasion (*P < 0.05; Student's t-test). This TGF-β response was inhibited sig-
nificantly by CystC and ∆14CystC expression (#P < 0.05; Student's t-test), whereas tonic NRK cell invasion was significantly inhibited only by 
CystC expression (*P < 0.05; Student's t-test). TGF-β1 significantly enhanced NMuMG cell invasion (*P < 0.05; Student's t-test), a response that 
was inhibited significantly by CystC and ∆14CystC expression (#P < 0.05; Student's t-test).Available online http://breast-cancer-research.com/content/7/5/R844
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TGF-β activation [38]. Cumulatively, the chemopreventive
activities of CystC will antagonize cancer cell responses to
TGF-β by inhibiting TGF-β binding [12] and by reducing TGF-
β bioavailability within tumor microenvironments, thereby alle-
viating the stimulation of EMT and tumor metastasis in late-
stage tumors by TGF-β.
Molecular dissection of TGF-β signaling systems necessary
for its induction of EMT has clearly established a role for
Smad2/3 in mediating EMT, particularly when coupled with
signals emanating from oncogenic Ras [13,39,40]. However,
Smad2/3-independent signaling has also been implicated in
TGF-β stimulation of EMT. For instance, TGF-β stimulates
EMT in cancers of the breast and other tissues by activating
phosphoinositide 3-kinase, Akt, RhoA, p160(ROCK), and p38
mitogen-activated protein (MAP) kinase [40-44]. In addition,
EMT in TGF-β-treated MECs is abrogated by measures that
inhibit β1 integrin activity [42], thus establishing the necessity
of β1 integrin expression for EMT stimulated by TGF-β. Finally,
by repressing Id2 and Id3 expression [45], inducing Snail and
SIP1 expression [46], and stimulating nuclear factor-κB activ-
ity [47], TGF-β regulates transcription factor activity operant in
mediating the transition from epithelial to mesenchymal cell
markers. We show that CystC inhibits the stimulation of
Smad2 phosphorylation by TGF-β and the subsequent induc-
tion of reporter gene expression in normal and cancer MECs.
Thus, reduced Smad2/3 signaling mediated by CystC proba-
bly underlies part of its ability to inhibit EMT stimulated by
TGF-β. Future studies need to address the role of CystC in
regulating Smad2/3-independent signaling stimulated by
TGF-β, as well as determining their contribution in preventing
the oncogenic activities of TGF-β in human breast cancer
cells.
Finally, we were quite surprised to find that CystC, despite its
ability to inhibit Smad2/3 signaling, failed to alter the growth-
suppressing activities of TGF-β. Although the molecular mech-
anism(s) underlying this unexpected CystC activity remains to
be elucidated, our findings suggest that CystC does not func-
tion to abrogate all TGF-β signaling, but may instead specifi-
cally alter and/or modulate certain aspects of TGF-β signaling
when complexed to TβR-II. In support of this supposition, we
find that activation of MAP kinases and Akt by TGF-β requires
high cytokine concentrations, whereas that of Smad2/3
requires markedly lower cytokine concentrations (more than
10-fold lower; data not shown). Mechanistically, we propose
that maximal stimulation of Smad2/3 by TGF-β requires mini-
mal receptor occupancy (that is, large receptor reserves),
whereas maximal stimulation of MAP kinases and AKT requires
maximal receptor occupancy (that is, no receptor reserves).
Thus, manipulations designed to antagonize the binding of
TGF-β to its receptors might elicit disproportionate inhibition
of TGF-β signaling systems, resulting in greater inhibition of
Smad2/3-independent versus Smad2/3-dependent path-
ways. Future studies need to address this important question
and determine which TGF-β signaling systems are preferen-
tially inhibited by the formation of CystC–TβR-II complexes in
normal and cancerous MECs.
Conclusion
Here we have shown the effectiveness of CystC in inhibiting
MEC EMT and fibroblast morphological transformation stimu-
lated by TGF-β, and in antagonizing TGF-β signaling in human
breast cancer cells. The ability of CystC to inhibit TGF-β sign-
aling in MECs occurs independently of its inactivation of
cathepsin protease activity, presumably by means of CystC–
TβR-II complex formation and the prevention of TGF-β binding
[12]. We suggest that CystC or its peptide mimetics ultimately
hold the potential to improve the therapeutic response of
human malignancies regulated by TGF-β, particularly cancers
of the breast. Experiments designed to test this hypothesis in
animal models of TGF-β oncogenicity and to identify CystC
determinants necessary in mediating TGF-β antagonism are
currently underway.
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